OpGen — Near-term adjustments with outlook unchanged

OpGen (NASDAQ: OPGN)

Last close As at 05/11/2024

USD1.75

−0.06 (−3.21%)

Market capitalisation

USD15m

More on this equity

Research: Healthcare

OpGen — Near-term adjustments with outlook unchanged

OpGen’s valuation case rests on its ability to develop and commercialize its suite of differentiated diagnostic products, focused on combating anti-microbial resistance (AMR). Q322 was marked by several developments on this front (see our last note), albeit offset with market caution in the current macroeconomic environment. This resulted in revised FY22 guidance (revenue of $2.5–3.0m versus c $4.6m previously) with the Q322 results. The delayed sales cycle conversions, along with the regulatory logjam in China, has prompted us to review our projections. Our revised estimates reflect near-term conservatism while largely maintaining our long-term outlook. Our overall valuation resets to $67.5m ($1.2/share) from $84.6m or $1.46/share (pending upcoming share consolidation). We also note that at current burn rates, OpGen is likely to need to raise funds in the near term to continue supporting its development plans.

Nidhi Singh

Written by

Nidhi Singh

Analyst

Healthcare

OpGen

Near-term adjustments with outlook unchanged

Estimates revision update

Pharma and biotech

15 December 2022

Price

US$0.13

Market cap

US$7m

Gross cash (US$m) at 3 October 2022 (including net funding proceeds)

13.3

Shares in issue

58.0m

Free float

92.5%

Code

OPGN

Primary exchange

Nasdaq

Secondary exchange

N/A

Share price performance

%

1m

3m

12m

Abs

(40.1)

(68.8)

(87.9)

Rel (local)

(37.8)

(68.2)

(85.3)

52-week high/low

US$1.12

US$0.12

Business description

OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. With the acquisition of Curetis in H120, management has the technology necessary to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, the company can provide diagnostic results in hours instead of days under legacy technologies.

Next events

FY22 results

March 2023

Analysts

Soo Romanoff

+44 (0)20 3077 5700

Jyoti Prakash

+44 (0)20 3077 5700

Nidhi Singh

+44 (0)20 3077 5700

OpGen is a research client of Edison Investment Research Limited

OpGen’s valuation case rests on its ability to develop and commercialize its suite of differentiated diagnostic products, focused on combating anti-microbial resistance (AMR). Q322 was marked by several developments on this front (see our last note), albeit offset with market caution in the current macroeconomic environment. This resulted in revised FY22 guidance (revenue of $2.5–3.0m versus c $4.6m previously) with the Q322 results. The delayed sales cycle conversions, along with the regulatory logjam in China, has prompted us to review our projections. Our revised estimates reflect near-term conservatism while largely maintaining our long-term outlook. Our overall valuation resets to $67.5m ($1.2/share) from $84.6m or $1.46/share (pending upcoming share consolidation). We also note that at current burn rates, OpGen is likely to need to raise funds in the near term to continue supporting its development plans.

Year end

Revenue ($m)

EBITDA*
($m)

PBT*
($m)

EPS*
($)

P/revenue
(x)

P/E
(x)

Net debt/
(cash) ($m)

12/20

4.2

(19.6)

(24.7)

(1.57)

1.7

N/A

6.7

12/21

4.3

(20.4)

(35.7)

(1.17)

1.6

N/A

(14.4)

12/22e

3.2

(19.9)

(25.4)

(0.51)

2.2

N/A

2.8

12/23e

5.3

(16.7)

(21.8)

(0.38)

1.3

N/A

24.0

Note: *EBITDA, PBT and EPS are normalized, excluding amortization of acquired intangibles, exceptional items and share-based payments.

Revisiting underlying assumptions

While FY22 has been marked by several business advancements for OpGen – it has signed two Acuitas AMR Gene Panel commercial contracts, successfully completed the urinary tract infection (UTI) test panel trial, launched ARES sequencing services in the United States and formed collaborations with FIND and BioVersys – the increasing complexity of its offering has extended the sales cycles. Following the FY22 guidance revision, ongoing macroeconomic tightness and clarity on the China regulatory path (Unyvero launch now anticipated in FY25 versus FY23 previously), we anticipate a relatively slower sales ramp for FY23–24, with momentum picking up from FY25 onwards. We have also incorporated the contribution from the FIND collaboration ($350k recognized in FY22 and the rest to be recognized in FY23) and BioVersys clinical trials ($100–200k over 18 months, starting in 2023) under collaboration revenue.

Stock consolidation in the pipeline

In December, OpGen announced its plans for a share consolidation (between 5:1 and 20:1), which we see as an effort to maintain the $1.0 share price threshold required for a Nasdaq listing. While the details are unavailable, we anticipate the consolidation will take place by February 2023, which marks the end of the 180-day extension granted to the company by Nasdaq.

Valuation: $67.5m or $1.2 per share

Updates to our assumptions and a lower net cash position result in a decrease in our valuation to $67.5m ($1.2/share) from $84.6m ($1.46/share) previously. Based on our projected cash burn rates and pro forma net cash of $0.8m at end Q322, we calculate a cash runway into Q123 and estimate the need to raise a total of $65m (previously $55m) before achieving profitability in FY27 (previously FY26).

Q322: Macroeconomic pressure following a strong H1

Following strong growth momentum in H122, Q322 top-line growth was adversely affected by a slowdown in international sales of Unyvero systems/cartridges and longer than expected sales cycles for Acuitas and ARES.

OpGen’s Q322 revenues were $449k, a 63.8% y-o-y decline from $1,239k in the prior year. Products sales, accounting for 80% of total revenue, were down by 44.2% y-o-y. Collaboration revenue declined by 85.4% y-o-y to $59k due to a lack of significant collaboration agreements during the quarter, while softer laboratory services (a decline of 83.9% y-o-y to $31k) were due to lower requirements for COVID-19 testing. The Q322 reported operating loss of $13.5m was significantly higher than $5.1m in the prior year, but was largely attributed to a $7.0m goodwill impairment charge recognized in Q322 as operating cash burn was $4.8m versus $5.1m in Q321. The write-off was related to the acquisitions of AdvanDx (July 2015) and Curetis (April 2020), reflecting OpGen’s assessment of the current market valuation of the assets based on progress to date and the outlook. Excluding the one-off impairment charge, operating expenses declined by 7.1% y-o-y in Q322. Research and development (R&D) and general and administrative (G&A) expenses were lower (by 14.7% and 3.2% y-o-y, respectively) due to reduced payroll costs. Sales and marketing (S&M) expenses increased by 2.8% y-o-y, pertaining to expansion of the sales team. Excluding the goodwill impairment charge, the normalized operating loss stood at $6.5m in Q322 versus $5.1m in Q321. Normalized loss before tax came in at $7.1m, up from $6.3m in Q321.

Management had previously guided for 25–50% revenue growth in the products and services segment in FY22 (including over 50% growth from the United States). However, longer than expected sales cycles for ARES and a slow ramp-up in Unyvero (international business) and Acuitas sales resulted in a FY22 revenue guidance downgrade to $2.5m–3.5m ($4.5m previously) when Q322 results were reported. The revised full-year guidance suggests Q422 revenues will be $0.6–1.1m, which we see as achievable, contingent on the anticipated contribution from the two Acuitas AMR installed systems and improved traction from Unyvero and ARES.

In accordance with the European Investment Bank debt restructuring in May 2022, OpGen is required to pay monthly instalments of $700k until April 2023, followed by the second and third tranches due for the amount of €3.0m ($3.2m) and €5.0m ($5.3m) plus accumulated deferred interest in June 2023 and June 2024, respectively. To support the debt repayment, development pipeline and commercialization efforts, the company raised $3.38m (gross) in October 2022 through an existing healthcare-focused institutional investor in exchange for a combined 9.66m in common stock and pre-funded warrants at $0.35/unit plus an additional 33.8k shares of Series C preferred stock. The investor was also issued warrants to purchase up to an aggregate of 9.66m in common stock, at an exercise price of $0.377/share. Following the fund-raise, OpGen had $13.3m in pro forma cash at Q322 and $12.5m in debt at end-Q322.

Estimate revisions

Based on the performance in the first nine months of FY22 (9M22) and directional guidance from management on near-term revenue potential, we have made certain changes to our forecasts, in particular for FY23–24. In addition to adjusting our FY22 revenue estimate in accordance with revised management guidance of $2.5–3.5m, we now incorporate a more protracted ramp-up in Unyvero sales in FY23–24, with stronger momentum from FY25 supported by a sales contribution from the UTI panel (we assume 80% probability of approval in 2024) in the United States and international market growth. For China, while we maintain our total sales potential expectations (€180m over eight years), approval and launch timelines have been pushed out from 2023 to 2025 following the recent communication by management on the requirement for resubmitting the regulatory filing under the new Chinese electronic filing system, potentially delaying the roll-out by 24–30 months. We continue to assume an 80% probability of approval but will revisit this assumption as the regulatory process progresses. For Acuitas, given the longer than anticipated sales cycles (c six months), we now incorporate slower growth in incremental account wins, although the long-term potential is unchanged. We have also included a contribution from the FIND collaboration ($350k in FY22 and the remaining $350k in FY23) and BioVersys clinical trials ($100–200k over 18 months, starting in 2023) under collaboration revenue. Our revised revenue estimates stand at $3.2m ($4.6m previously) and $5.3m ($7.7m previously) for FY22 and FY23, respectively.

We have also made certain adjustments to our expense estimates based on the 9M22 run rate. We have adjusted R&D estimates to $8.7m ($9.3m previously) for FY22 and $8.2m ($8.4m previously) for FY23, while SG&A estimates decreased to $13.7m (FY22) and $12.9m (FY23) from $14.0m and $13.5m, respectively. Reflecting the changes, we calculate an operating loss of $22.5m in FY22 and $18.9m in FY23 (vs $21.1m and $18.5m previously, respectively) (Exhibit 1).

Exhibit 1: Key change to forecasts

FY21

FY22e

FY23e

$’000s

Actual

Old

New

Change (%)

Old

New

Change (%)

Total revenues

4,306

4,623

3,172

-31.4%

7,713

5,283

-31.5%

-- Product sales

2,657

3,384

2,409

-28.8%

6,599

4,549

-31.1%

-- Lab services

813

569

163

-71.4%

512

146

-71.4%

-- Collaboration revenue

836

669

601

-10.2%

602

588

-2.3%

Gross profit

1,458

2,159

(25)

-101.2%

3,364

2,208

-34.4%

Gross margin

33.8%

46.7%

-0.8%

43.6%

41.8%

Adjusted EBITDA

(20,388)

(18,546)

(19,886)

7.2%

(16,308)

(16,678)

2.3%

Adjusted EBIT

(23,102)

(21,148)

(22,488)

6.3%

(18,524)

(18,894)

2.0%

Adjusted EPS (c)

(117)

(49.7)

(51.1)

2.8%

(44.4)

(37.6)

-15.3%

Source: Company reports, Edison Investment Research

Valuation

Following the aforementioned changes to our estimates, we reduce our valuation to $67.5m or $1.2 per share from $84.6m or $1.46 per share previously. While the decline in enterprise value was driven by lower net present values (NPVs) for Unyvero (including China) and the Acuitas AMR Gene Panel, the equity value has also been affected by a lower net cash position ($0.8m versus $2.7m previously). In addition, the per-share valuation was affected by the higher number of shares outstanding following the exercise of pre-funded warrants from the October 2022 equity raising (58m versus 53.7m previously). On a product/segment level, we reduce our risk-adjusted NPV for Unyvero (excluding China) to $98.1m from $105.4m previously, assuming a slower ramp-up to peak sales for the Unyvero A50 system and assays in both the United States and international markets. Similar adjustments have been made for the Acuitas AMR Gene Panel given the longer sales cycles (revised rNPV of $14.2m versus $18m previously). For Unyvero China, the rNPV goes down to $20.5m (versus $26.2m previously) as we push our commercialization timelines to 2025. However, the underlying longer-term outlook remains unchanged, as indicated by only minor changes to our peak sales estimates across the segments (expected in 2035). While we have limited information available for the Aresdb dataset, we continue to use the carrying value of the asset in our valuation. We will update this figure as more information becomes available.

We expect the pro forma gross cash balance of c $13.3m (including $3m in net proceeds from the private placement in October) to fund operations into Q123 based on an anticipated operating cash burn of c $5m per quarter and $700k/month in EIB loan repayment. We therefore anticipate the need to raise $20m in funds imminently, followed by another $45m over FY23–26, before reaching the scale to fund operations from internally generated cash flow (FY27).

Exhibit 2: OpGen’s valuation

Product

Main indication

Status

Probability of successful commercialization

Launch year

Peak sales ($m)

Patent protection

rNPV
($m)

Unyvero excluding China

Lower respiratory

Market

100%

2020

134.0

2040

98.1

 

UTI (US)

Clinical

80%

2024

 

IJI (US)

Preclinical

50%

2025

 

 

Unyvero - China

HPN

Registration

80%

2025

41.2

2040

20.5

Acuitas AMR Panel

AMR

Market

100%

2022

20.2

2040

14.2

Aresdb (book value)

Bioinformatics

Market

 

 

 

 

4.8

Unyvero A30 book value and others

IJI

Preclinical

 

 

 

 

9.0

Unallocated R&D costs

(24.7)

G&A costs

(55.3)

Pro-forma net cash (at 3 October 2022)

 

 

 

 

 

 

0.8

Total firm value

67.5

Total shares outstanding (m)

58.0

Value per share ($)

 

 

 

 

 

 

1.2

Source: Edison Investment Research

Exhibit 3: Financial summary

$'000s

2019

2020

2021

2022e

2023e

Year end 31 December

GAAP

GAAP

GAAP

GAAP

GAAP

PROFIT & LOSS

 

 

Revenue

 

 

3,499

4,214

4,306

3,172

5,283

Cost of Sales

(1,632)

(3,848)

(2,848)

(3,197)

(3,075)

Gross Profit

1,867

366

1,458

(25)

2,208

Sales, General and Administrative Expenses

(8,496)

(12,367)

(13,649)

(13,735)

(12,904)

Research and Development Expense

(5,121)

(9,965)

(10,911)

(8,729)

(8,199)

EBITDA

 

 

(10,829)

(19,631)

(20,388)

(19,886)

(16,678)

Operating Profit (before amort. and excepts.)

 

(11,750)

(21,966)

(23,102)

(22,488)

(18,894)

Intangible Amortisation

0

0

0

0

0

Other

0

0

0

0

0

Exceptionals

(522)

(752)

(171)

(6,976)

0

Operating Profit

(12,272)

(22,718)

(23,273)

(29,464)

(18,894)

Net Interest

(178)

(3,294)

(4,754)

(2,942)

(2,900)

Other

2

(66)

(6,735)

474

0

Profit Before Tax (norm)

 

 

(11,928)

(24,742)

(35,742)

(25,375)

(21,794)

Profit Before Tax (reported)

 

 

(12,447)

(26,078)

(34,762)

(31,932)

(21,794)

Tax

0

(132)

(44)

0

0

Deferred tax

0

0

0

0

0

Profit After Tax (norm)

(11,928)

(24,875)

(35,786)

(25,375)

(21,794)

Profit After Tax (reported)

(12,447)

(26,211)

(34,806)

(31,932)

(21,794)

Average Number of Shares Outstanding (m)

1.6

15.8

36.7

49.7

58.0

EPS - normalised (c)

 

 

(737.70)

(157.43)

(117.12)

(51.08)

(37.58)

EPS - Reported ($)

 

 

(7.70)

(1.66)

(1.14)

(0.64)

(0.38)

Dividend per share (c)

0.0

0.0

0.0

0.0

0.0

BALANCE SHEET

Fixed Assets

 

 

3,755

32,863

31,924

20,491

18,688

Intangible Assets

1,418

24,606

21,983

13,503

12,548

Tangible Assets

2,133

5,791

5,917

4,738

3,890

Other

203

2,466

4,024

2,250

2,250

Current Assets

 

 

6,667

16,888

39,743

12,873

8,122

Stocks

473

1,486

1,239

1,279

1,227

Debtors

568

653

1,172

608

1,013

Cash

2,708

13,360

36,080

9,735

4,632

Other

2,918

1,388

1,250

1,250

1,250

Current Liabilities

 

 

4,939

7,372

19,917

14,795

13,689

Creditors

4,565

6,673

5,398

5,396

5,170

Short term borrowings

374

699

14,519

9,399

8,519

Long Term Liabilities

 

 

1,190

21,188

10,533

6,087

22,722

Long term borrowings

329

19,379

7,176

3,096

20,116

Other long term liabilities

860

1,809

3,356

2,990

2,606

Net Assets

 

 

4,293

21,191

41,217

12,482

(9,601)

CASH FLOW

Operating Cash Flow

 

 

(11,506)

(23,397)

(21,479)

(17,978)

(16,783)

Net Interest

0

0

0

0

0

Tax

0

0

0

0

0

Capex

(32)

(130)

(1,984)

(397)

(413)

Acquisitions/disposals

0

1,267

0

0

0

Equity Financing

13,062

33,793

48,159

4,370

0

Dividends

0

0

0

0

0

Other

0

0

(266)

0

0

Net Cash Flow

1,524

11,533

24,430

(14,005)

(17,196)

Opening net debt/(cash)

 

 

(3,514)

(2,005)

6,717

(14,385)

2,760

HP finance leases initiated

0

0

0

0

0

Exchange rate movements

(19)

(2)

(5)

(13)

(4)

Other

(3013)

(20,254)

(3,322)

(3,127)

(4,043)

Closing net debt/(cash)

 

 

(2,005)

6,717

(14,385)

2,760

24,004

Source: Company reports, Edison Investment Research


General disclaimer and copyright

This report has been commissioned by OpGen and prepared and issued by Edison, in consideration of a fee payable by OpGen. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

General disclaimer and copyright

This report has been commissioned by OpGen and prepared and issued by Edison, in consideration of a fee payable by OpGen. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on OpGen

View All

Latest from the Healthcare sector

View All Healthcare content

Research: Investment Companies

The Merchants Trust — Higher gearing to take advantage of opportunities

The Merchants Trust (MRCH) is managed by Simon Gergel, chief investment officer of UK equities at Allianz Global Investors (AllianzGI). He highlights that the remaining £16m of the trust’s £42m credit facility has recently been drawn down, taking gearing from c 13% to c 15%. This indicates that the manager, and MRCH’s board, see good value in the UK market, particularly in the type of stocks that fit Gergel’s disciplined investment criteria. The manager continues to seek undervalued companies with solid fundamentals, aiming to generate a high and growing level of income and long-term capital growth. MRCH has a commendable performance track record, outperforming the broad UK market over the short, medium and longer term. It also ranks highly versus its peers in the 22-strong AIC UK Equity Income sector. The trust’s annual dividend has grown for the last 40 consecutive years.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free